Portfolio Building Block ... (PBPH)
NasdaqGM: PBPH
· Echtzeitkurs · USD
27.99
+0.00 (0.00%)
Zum Schluss: Aug 13, 2026, 3:55 PM
27.99
+0.00%
Nachbörslich: 4:10 PM
Portfolio Building Block World Pharma And Biotech Index ETF (PBPH) ETF Price, Holdings & Analysis
0.00% (1D)
| Geld | 21.91 |
| Marktkapitalisierung | n/a |
| Fondsvermögen | 952.24 Mio |
| NAV | 27.96 |
| Beta | k.A. |
| EPS (ttm) | k.A. |
| PE Ratio (ttm) | 25.78 |
| Ausstehende Anteile | k.A. |
| Auflagedatum | Nov 25, 2025 |
| Brief | 32.89 |
| Volumen | 75,714 |
| Ø Vol. (20D) | 139,251 |
| Eröffnung | 28.08 |
| Vortagesschluss | 27.99 |
| Tagesspanne | 27.93 - 28.08 |
| 52-Wk Range | 24.18 - 28.29 |
| Positionen | k.A. |
| Kostenquote | 0.13% |
Über PBPH
The fund uses a “passive management” approach to track the performance, before fees and expenses, of the index. The index is constructed using a rules-based methodology that identifies companies in the pharmaceutical and/or biotechnology industries with publicly traded ordinary shares listed on major stock exchanges in developed markets, as classified by BITA GmbH. Under normal circumstances, the fund will invest at least 80% of the fund’s net assets in component securities that make up the index. The fund is non-diversified.
Anlageklasse Equity
Tickersymbol PBPH
Auflagedatum Nov 25, 2025
Anbieter Portfolio Building Block Etfs
Website Fonds-Homepage
Börse NasdaqGM
Top 10 Positionen 61.99% insgesamt
| Name | Symbol | Gewicht |
|---|---|---|
| Eli Lilly And Co | LLY | 15.23% |
| Johnson & Johnson | JNJ | 9.68% |
| Abbvie Inc | ABBV | 6.96% |
| Merck & Co Inc | MRK | 5.05% |
| Roche Holding Ag Ord... | ROP.SW | 4.75% |
| Amgen Inc | AMGN | 4.64% |
| Novartis Ag Register... | NOVN.SW | 4.48% |
| Astrazeneca PLC | AZN.L | 3.90% |
| Gilead Sciences Inc | GILD | 3.78% |
| Novo Nordisk As Clas... | NOVO-B.CO | 3.52% |
Dividenden Dividendenrendite 0.08%
| Ex-Dividende | Betrag | Zahldatum |
|---|---|---|
| Dec 24, 2025 | $0.0230 | k.A. |
vor 2 Monaten · etf.com
Fastest Growing ETFs of 2026<p>These ETFs have seen extraordinary growth this year.</p>